Ningmitai Capsules relieve lower urinary tract symptoms in patients with benign prostatic hyperplasia :A short-term clinical observation
DENG Zhe-xian
JI Ling-xiao
ZHANG Yi-rong
LI Cheng-di
CAI Jian
JIANG Hai-hong
Abstract：Objective:To observe the clinical effect and safety of the Chinese patent medicine Ningmitai Capsules (NMT) in relieving lower urinary tract symptoms (LUTS) in the patient with benign prostatic hyperplasia (BPH).Methods:We randomly assigned 40 BPH patients to an experimental and a control group of equal number to receive oral administration of NMT at 4 capsules tid and terazosin hydrochloride tablets at 2 mg qd,respectively,both for 14 days.At 7 and 14 days after medication,we recorded and compared the International Prostate Symptoms Score (IPSS),maximum urinary flow rate (Qmax),quality of life (QoL) scores,results of urinalysis and blood routine examination,and indexes of hepatic and renal function.Results:Both NMT and terazosin significantly improved the total IPSS score,the IPSS scores in the storage and voiding phases,increased Qmax and urine output,reduced post-void residual urine (PVR),and improved the QoL of the patients.The patients of the NMT group showed a better relief of incomplete bladder emptying,more improved QoL and fewer adverse reactions,while those treated with terazosin achieved a better attenuation of weak urine stream and PVR.Conclusion:NMT is safe and effective in relieving LUTS in BPH patients.Each of NMT and terazosin has its own advantages in attenuating urinary tract irritation and obstruction,but whether their combination may produce a better effect on LUTS and the specific mechanisms of NMT improving acute symptoms of BPH are yet to be further studied.
Keywords：benign prostatic hyperplasialower urinary tract symptomsNingmitai CapsulesterazosinInternational Prostate Symptoms Scoreuroflowmetryquality of life
Publication Date：2018-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：6( 72-77 )